Discover
VRTX
Vertex Pharmaceuticals Incorporated
530.37
1 x 530.39
1 x 530.55
bid
ask
+
6.46
1.23%
01:31 PM
timesize
| Ytd | 16.99% | |
| 1y | 41.64% |
522.01
day range
531.80
374.46
52 week range
530.46
| Open | 525.00 | Prev Close | 523.91 | Low | 522.01 | High | 531.80 | Mkt Cap | 134.64B |
| Vol | 427.95K | Avg Vol | 1.58M | EPS | 19.03 | P/E | 27.88 | Forward P/E | 22.96 |
| Beta | 0.30 | Short Ratio | 2.45 | Inst. Own | 98.75% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-03 | 50-d Avg | 474.68 | 200-d Avg | 455.17 | 1yr Est | 559.28 |
| Income Statement | |||
| Total Revenue | 3.33B | ||
| Revenues (USD) | 3.33B | ||
| Cost of Revenue | 489.20M | ||
| Gross Profit | 2.84B | ||
| Operating Expenses | 1.60B | ||
| Research and Development Expense | 993.80M | ||
| Selling, General and Administrative Expense | 582.20M | ||
| Operating Income | 1.25B | ||
| Income Tax Expense | 292.00M | ||
| Net Income | 1.10B | ||
| Net Income Common Stock | 1.10B | ||
| Net Income Common Stock (USD) | 1.10B | ||
| Consolidated Income | 1.10B | ||
| Earnings per Basic Share | 4.34 | ||
| Earnings per Basic Share (USD) | 4.34 | ||
| Earnings per Diluted Share | 4.31 | ||
| Earning Before Interest & Taxes (EBIT) | 1.39B | ||
| Earning Before Interest & Taxes (USD) | 1.39B | ||
| Weighted Average Shares | 253.70M | ||
| Weighted Average Shares Diluted | 255.20M | ||
| Balance Sheet | |||
| Cash and Equivalents | 6.14B | ||
| Cash and Equivalents (USD) | 6.14B | ||
| Investments | 7.50B | ||
| Investments Current | 1.71B | ||
| Investments Non-Current | 5.79B | ||
| Trade and Non-Trade Receivables | 2.13B | ||
| Current Assets | 12.54B | ||
| Property, Plant & Equipment Net | 3.33B | ||
| Total Assets | 27.42B | ||
| Total Debt | 1.98B | ||
| Current Liabilities | 3.94B | ||
| Debt Non-Current | 1.98B | ||
| Total Liabilities | 7.18B | ||
| Accumulated Retained Earnings (Deficit) | 15.69B | ||
| Accumulated Other Comprehensive Income | 48.50M | ||
| Shareholders Equity | 20.25B | ||
| Shareholders Equity (USD) | 20.25B | ||
| Assets Non-Current | 14.88B | ||
| Total Debt (USD) | 1.98B | ||
| Goodwill and Intangible Assets | 1.50B | ||
| Inventory | 1.77B | ||
| Liabilities Non-Current | 3.24B | ||
| Trade and Non-Trade Payables | 429.50M | ||
| Tax Assets | 3.01B | ||
| Cash Flow | |||
| Depreciation, Amortization & Accretion | 56.50M | ||
| Net Cash Flow from Financing | -426.70M | ||
| Net Cash Flow / Change in Cash & Cash Equivalents | 649.20M | ||
| Capital Expenditure | -112.20M | ||
| Issuance (Purchase) of Equity Shares | -426.10M | ||
| Net Cash Flow from Investing | -45.80M | ||
| Net Cash Flow - Investment Acquisitions and Disposals | 68.10M | ||
| Net Cash Flow from Operations | 1.13B | ||
| Effect of Exchange Rate Changes on Cash | -3.70M | ||
| Share Based Compensation | 170.20M | ||